Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial.
David M G HalpinRobyn KendallSoham ShuklaAlan A MartinDhvani ShahDawn MidwinterKai-Michael BeehJanwillem W H KocksPaul W JonesChris ComptonNancy A RisebroughAfisi S IsmailaPublished in: International journal of chronic obstructive pulmonary disease (2022)
Based on this analysis, in a UK setting, FF/UMEC/VI would improve health outcomes and reduce costs compared with non-ELLIPTA MITT for the treatment of patients with symptomatic COPD. SITT may help to reduce the clinical and economic burden of COPD and should be considered by physicians as a preferred treatment option.